The Importance of Ocular Drug Delivery Platform Development

Ophthalmic formulations are intended for application to the anterior surface of the eye (topical route), intraocular, periocular delivery, or in combination with eye devices. Ophthalmic dosage forms may be liquid, semi-solid, solid or mixed. While many effective drugs are available to treat most ocular diseases, many ocular barriers such as the tear film, cornea, conjunctiva, and blood-ocular barrier hinder their therapeutic effectiveness. Efficient ocular absorption requires adequate corneal penetration and effective precorneal residence time. This is to achieve and maintain acceptable drug concentrations with a minimum amount of active therapeutic ingredients. Therefore, developing novel, safe, and patient-compliant drug delivery strategies is one of the priorities of ophthalmic drug development, which may overcome these barriers and maintain drug levels in tissues.

Fig. 1. Ocular anatomic barriers and routes of drug administration. (Gote V, et al., 2019)

What Is Ace Therapeutics Doing for Ocular Drug Delivery System Development?

One of the main challenges facing ocular drug development today is ocular drug delivery. How to deliver therapeutic concentrations of effective drugs targeting ocular tissues with minimal side effects is the research focus of global pharmacologists and formulation scientists. As one of the world's leading providers of eye disease solutions, Ace Therapeutics is committed to improving the lives of patients with eye diseases through the discovery and development of novel ocular delivery systems. In support of this mission, ur talented scientists are developing multiple ocular drug delivery system for anterior and posterior segment diseases to improve the lives of patients.

Explore Our Capabilities

With a complete pharmaceutical and advanced technology background, Ace Therapeutics has successfully completed a large number of drug delivery projects for ocular delivery systems, with a wide range of services covering formulation, development, science and application. The ocular delivery system we developed has the advantages of sustained release, enhanced penetration into ocular tissue, precise dosage and ease of administration. Including but not limited to:

• Solid Lipid Nanoparticle Development Services for Ocular Drug Delivery
• Development Services for Liposomal Ocular Drug Delivery Systems
• Dendrimer Nanoparticle Development Services for Ocular Drug Delivery
• Development Services for Hydrogel-Based Ocular Drug Delivery Systems
• Development Services for Nanomicelle-Based Ocular Drug Delivery Systems
• Development Services for Microneedle-Based Ocular Drug Delivery Systems
• Ocular Implant Development Services for Drug Delivery
• Ocular Insert Development Services for Drug Delivery

What Can Ace Therapeutics Do?

• Various types of ocular delivery system development.
• Controlled/sustained release ophthalmic drug delivery system.
• Pre-formulation, formulation feasibility and prototype development.
• Various identification and standardization methods.
• Process optimization (design of experiments) and sterile filtration.

As a contract provider of solutions for ocular diseases, in order to better understand unmet needs, successful delivery of ocular drug delivery systems. Ace Therapeutics is developing several advanced ocular delivery systems for our customers. Our pioneering research, objectified workflows and state-of-the-art equipment can help you achieve milestone development. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

1. Gote V, Sikder S, Sicotte J, et al. Ocular Drug Delivery: Present Innovations and Future Challenges. J Pharmacol Exp Ther. 2019;370(3):602-624.
2. Patel A, Cholkar K, Agrahari V, et al. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47-64.
3. Silva-Cunha A. Advances in Ocular Drug Delivery Systems. Pharmaceutics. 2021 Sep 1;13(9):1383.

• Ocular Toxicology Services
• Ocular Pharmacology Services
• Ocular Pharmacokinetic Services
• Ocular Histology and Histopathology Services
• Customized Non-GLP Ophthalmic Program Development Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit